Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07346196 · ClinicalTrials.gov registry record · Phase 2
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
A Phase 2 study, sponsored by University of Chicago.
- Not yet
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07346196: Clinical Trial Phase 2 study, sponsored by University of Chicago.
NCT07346196 is a Phase 2 study that has not yet begun recruiting, run by University of Chicago. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07346196, a Phase 2 study, has not yet begun recruiting, sponsored by University of Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.
Primary Outcome
To assess the overall response rate (ORR) of induction cemiplimab and chemotherapy, with or without fianlimab in patients with locoregionally advanced squamous cell carcinoma of the head and neck. ORR will be measured and compared between the two treatment groups using a pick-the-winner design.
Interventions
- DRUG Carboplatin
- DRUG Cemiplimab
- DRUG Paclitaxel
- RADIATION Radiation
- DRUG Fianlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2027-02-07 |
| Est. Completion | 2031-08-22 |
| Phase | Phase 2 |
What is known before NCT07346196 opens enrollment
NCT07346196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT07346196 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07346196 about?
NCT07346196 is a clinical study titled "A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck". The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.
What is the current status of trial NCT07346196?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2027-02-07. Estimated completion is 2031-08-22.
What interventions are being tested in trial NCT07346196?
The interventions under investigation include: Carboplatin (DRUG), Cemiplimab (DRUG), Paclitaxel (DRUG), Radiation (RADIATION), Fianlimab (DRUG).
Who is sponsoring clinical trial NCT07346196?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07346196's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI